Research reviews show people tapering off GLP-1 weight-loss drugs regain lost weight quickly—around 18 months—while benefits fade sooner without long-term support.
For many people, GLP-1s like Ozempic and Wegovy feel like a turning point—until the question of stopping arrives.
New analyses of prior research suggest that once people come off these weight-loss medications, the pounds tend to return faster than many expect, with weight regain projected within about 18 months.. The findings add weight to a message that is increasingly common in obesity medicine: weight loss may need ongoing support rather than a short, time-limited “course.”
The evidence comes from a review published in the British Medical Journal in January, which pulled together 37 earlier studies involving roughly 9,000 people.. Across those trials, researchers concluded that stopping weight management medications is followed by rapid regain and a reversal of some of the positive changes seen in blood pressure, cholesterol patterns, and other cardiometabolic markers.. They also found that regaining after medication stopped happened more quickly than regain after behavioural programmes—such as structured dieting and exercise.
GLP-1 drugs have become widely used for weight management, partly because they affect appetite in multiple ways.. They can reduce cravings, slow digestion, and help people feel full for longer, which often leads to eating less without constant willpower battles.. Medications in this group include semaglutide—used in products such as Ozempic and Wegovy—and other related agents used under different brand names.
What makes the new warnings particularly important is the framing: obesity is described as a chronic, relapsing condition, not a temporary phase.. The review notes that losing weight can improve cardiovascular risk factors, and it points to longer-term trial evidence suggesting benefits can extend over years for people with established cardiovascular disease.. But the review also says that when weight returns after treatment ends, some of those protective signals soften.. One analysis projection suggests weight regain can be faster—around 0.8 kg per month—with a return toward baseline weight within approximately 1.5 years after cessation.
That timing matters for everyday risk management.. People don’t experience health outcomes only at the end of a study calendar; they live with trends in weight, glucose control, blood pressure, and lipids over time.. Rapid regain can make it harder to sustain improvements that might otherwise lower overall risk, even if the initial weight loss was meaningful and life-changing.
There is also a practical nuance in how the review gathered its data.. The studies included not just specific named products, but categories of drugs “currently or previously licensed for weight loss,” and they treated drugs within the same class as comparable where there was reason to believe they share effects.. Alongside semaglutide, researchers considered other active ingredients used for weight management, including tirzepatide and liraglutide.
A second study published last month echoed the same overall pattern.. Researchers reported that when individuals stopped taking these medications, they experienced rapid initial weight regain, and by 52 weeks they had regained about 60% of the original weight loss in the group studied.. In other words, even when people manage to avoid a complete rollback, much of the progress can still return within a year.
The human explanation offered by clinicians-in-training helps clarify why the numbers can look so blunt.. Cambridge medical student Brajan Budini described these therapies as “brakes on our appetite,” meaning they alter hunger signals and fullness.. When treatment stops, the brake comes off—so appetite can rise again and eating patterns can shift back toward what they were before medication.
At the same time, the studies also suggest not all outcomes are identical.. Another reason some people may not return completely to their starting weight—even after a year—could be the habits formed during treatment.. If medication helps people eat smaller portions, or choose more balanced meals, those changes may linger beyond the prescription end date.
That’s where the discussion moves from a clinical warning to a planning conversation.. Medical student Steven Luo said that when stopping weight-loss drugs, both doctors and patients should anticipate the risk of regain and actively consider ways to reduce it.. The message reportedly leans toward combining medication with an approach to diet and exercise, rather than relying on the drug alone.
Novo Nordisk, the company behind Wegovy and Ozempic, responded to the earlier BMJ findings by emphasizing the chronic nature of obesity and the need for ongoing treatment in order to preserve health improvements—drawing a parallel to how other long-term conditions are managed.
For patients, the takeaway is not necessarily that stopping is “wrong,” but that stopping appears to carry measurable chances of rapid reversal unless support continues in another form.. As obesity care evolves, the key question may shift from how long to use GLP-1s, to how to build a sustainable long-term plan—so the benefits don’t fade as quickly as the medication does.